BAY 1436032

Drug Profile

BAY 1436032

Alternative Names: BAY1436032

Latest Information Update: 06 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Bayer
  • Class Antineoplastics
  • Mechanism of Action Isocitrate dehydrogenase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Solid tumours

Most Recent Events

  • 14 Jun 2017 Phase-I clinical trials in Acute myeloid leukaemia (Late-stage disease, Second-line therapy or greater) in USA (PO) (NCT03127735)
  • 28 Apr 2017 Bayer plans a phase I trial for Acute myeloid leukaemia (Late-stage disease, Second-line therapy) in USA and Germany (NCT03127735)
  • 15 Dec 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top